Literature DB >> 29457494

Management of Phenobarbital and Apixaban Interaction in Recurrent Cardioembolic Stroke.

Philip K King, Trevor A Stump, Allyn M Walkama, Benjamin M Ash, Susana M Bowling.   

Abstract

Entities:  

Year:  2018        PMID： 29457494     DOI： 10.1177/1060028018759938

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN： 1060-0280            Impact factor:   3.154


× No keyword cloud information.
  5 in total

Review 1.  Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.

Authors:  Sara R Vazquez
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS).

Authors:  Amichai Perlman; Maor Wanounou; Rachel Goldstein; Lotan Choshen Cohen; Daniel E Singer; Mordechai Muszkat
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

3.  Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.

Authors:  Silvia Fernandez; Camille Lenoir; Caroline Samer; Victoria Rollason
Journal:  Pharmacol Res Perspect       Date:  2020-10

Review 4.  Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review.

Authors:  Allen Li; Ming K Li; Mark Crowther; Sara R Vazquez
Journal:  Thromb Res       Date:  2020-08-11       Impact factor: 3.944

5.  Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study.

Authors:  Amichai Perlman; Rachel Goldstein; Lotan Choshen Cohen; Bruria Hirsh-Raccah; David Hakimian; Ilan Matok; Yosef Kalish; Daniel E Singer; Mordechai Muszkat
Journal:  CNS Drugs       Date:  2021-02-17       Impact factor: 5.749
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.